Navigation Links
Ranbaxy and Pfizer Settle Lipitor Litigation Worldwide
Date:6/18/2008

Ranbaxy Will Market Generic Atorvastatin in the U.S. With 180 Days

Exclusivity From Nov. 30, 2011

Agreement Also Resolves Caduet, Accupril Litigation in the US

GURGAON, Harayana, India and PRINCETON, N.J., June 18 /PRNewswire/ -- Ranbaxy Laboratories Limited (Ranbaxy), announced today that it has entered into an agreement with Pfizer Inc. to settle most of the patent litigation worldwide involving Atorvastatin (Lipitor), the world's most-prescribed cholesterol-lowering medicine. This decision will allow for an earlier introduction of a generic formulation that will benefit patients and many healthcare systems throughout the world. Lipitor is the world's largest selling drug with worldwide sales in 2007 of $12.7 billion.

The agreement pertains solely to Ranbaxy and its affiliates and does not cover legal challenges to the Lipitor patents involving other generic manufacturers. However, as Ranbaxy was the first generic challenger to the listed Lipitor patents, it retains the right to the marketing exclusivity of 180 days in the United States. Under the terms of the agreement, Ranbaxy will have a license to sell generic versions of Atorvastatin and the fixed-dose combination of Atorvastatin-Amlodipine besylate in the United States effective Nov. 30, 2011.

Welcoming the development, Malvinder Mohan Singh, CEO and MD, Ranbaxy Laboratories Ltd., said, "This comprehensively settles outstanding issues between Ranbaxy and Pfizer bringing to closure a number of ongoing patent disputes. It also provides certainty and visibility to the launch of Ranbaxy's Generic Atorvastatin, with 180-day market exclusivity in the US and an early entry in other markets. This will make the worlds largest selling drug more accessible to patients who will gain from the timely availability of an affordable quality option."

Ranbaxy will also have a license to sell Atorvastatin on varying dates in an additional 7 countries, includi
'/>"/>

SOURCE Ranbaxy Laboratories Limited
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Ranbaxy to Bring in Daiichi Sankyo as Majority Partner; Strategic Combination Creates Innovator and Generic Pharma Powerhouse
2. Ranbaxy Receives Final Approval to Manufacture and Market Cetirizine Hydrochloride Oral Solution
3. Ranbaxy Gains Approval to Manufacture and Market Cefuroxime Axetil for Oral Suspension
4. Ranbaxy Receives Final Approval to Manufacture and Market Cetirizine Hydrochloride Tablets (OTC), 5mg and 10mg
5. Ranbaxy Receives Tentative Approval For Valsartan Tablets
6. Ranbaxy First to Gain Approval to Manufacture and Market Clarithromycin for Oral Suspension, USP
7. Ranbaxy Gains Approval to Manufacture and Market Carvedilol Tablets in the U.S. Market
8. Ranbaxy Receives Tentative Approval to Manufacture and Market Galantamine Tablets on an Exclusive Basis
9. Novartis, Pfizer and Merck Take the Lead on Strong Relationships with Physicians, as Doctors Demand an Expanding Set of Services
10. Pfizers work on penicillin for World War II becomes a National Historic Chemical Landmark
11. AUDIO from Medialink and Pfizer: Free Programs for Uninsured Men and Women Who Need Help Paying for Medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... Loffler Companies has been selected as ... an online information and news publication for resellers of ... consecutive year Loffler has earned this prestigious award and ... Dealer Awards honor the best and the brightest in ... honorees were chosen for their innovative marketing and sales ...
(Date:11/26/2014)... Senior Planning Services, providing “expert guidance ... organization providing the adult demographic education and access ... navigate the rough seas of applying for Medicaid. Part ... the topic of Medicaid eligibility and proper planning, while ... applying for this coverage. , Senior Planning Services ...
(Date:11/26/2014)... Call 866-997-4948 (Us-Canada Toll Free) Tel: ... details on sales(at)researchmoz(dot)us , Researchmoz.us announces a new ... 2014" with deep study of the report on the ... blood sugar. The global glucose monitoring market has a ... number of diabetics in the world. Their numbers have ...
(Date:11/26/2014)... Rouge, Louisiana (PRWEB) November 26, 2014 ... neck pain relief and specialists in minimally invasive ... K. Samer Shamieh into the rapidly growing provider ... specialists. The addition coincides with the network’s ... reliable medical treatment for Louisiana residents who are ...
(Date:11/26/2014)... (HealthDay News) -- Youngsters who enter puberty early are ... Early puberty was linked with a number of ... high anxiety levels, according to the researchers. Early puberty ... with family and peers, and having friends who were ... Although the study found an association between early puberty ...
Breaking Medicine News(10 mins):Health News:Loffler Companies Recognized as an Elite Dealer for Sixth Consecutive Year 2Health News:Senior Planning Services Teams Up with SeniorNet To Educate Seniors On Medicaid Planning 2Health News:Latest Report on Diabetes Market 2014 - Global Market Size, Share, Trends and Forecast by Researchmoz.us 2Health News:Latest Report on Diabetes Market 2014 - Global Market Size, Share, Trends and Forecast by Researchmoz.us 3Health News:Louisiana Back Institute Welcomes Dr. K. Samer Shamieh into Medical Provider Network 2Health News:Early Puberty Linked to Increased Risk of Depression in Teens 2
... the results of Kryptiq's Care Manager Diabetes Module at ... conference. // ,This module showed ... who benefited. The one year study showed that the ... levels. Providence Medical Group documented a 250% increase in ...
... Internet that enabled gay men contact in Hong Kong has ... men according to a latest report. // ,Government ... and November 2005, had HIV with similar gene sequencing, the ... made when all the men sought medical help after contracting ...
... Detecting cancer of the esophagus could be as simple as swallowing ... the fervent efforts of Cambridge University researchers // that can detect ... It is the ninth most commonly occurring tumor in the Britain. ... gently scraping cells from the gut wall that are then tested ...
... encouraged Americans to open health savings accounts (HSAs). He said ... costs. It was // well received by many ... means by which the doctors cure the country's health finance ... for Hewitt Associates said that HSA model creates obstacles to ...
... A new device developed to detect elevated levels of ... in a baby during childbirth. // This finding ... performed, as any suspicion of oxygen deprivation is a ... device, developed by researchers at Warwick University has been ...
... 2020 road accidents will be the third highest threat ... diarrhoea and HIV/AIDS.// ,In South Asia alone, ... in 2000 to 330,000 in 2020, a 144 percent ... WHO report 'World Report on Road Traffic Injury Prevention' ...
Cached Medicine News:Health News:Kryptiq Care Manager Diabetes Module Effective In Managing Diabetes 2Health News:President Bush proposes HSAs scheme for the benefit of both the workers and the country 2Health News:President Bush proposes HSAs scheme for the benefit of both the workers and the country 3Health News:New Sensor To Monitor Oxygen Deprivation In Babies During Birth 2Health News:Road accidents greater threat than AIDS, TB: WHO 2
(Date:11/26/2014)... , Nov. 25, 2014  Unilife Corporation (NASDAQ: UNIS, ... drug delivery systems, today announced that its Chairman and ... at the Piper Jaffray 26th Annual Healthcare Conference at ... on Tuesday, December 2, 2014. The ... a "live" listen only Webcast. To listen, please go ...
(Date:11/26/2014)... YORK and HERZLIYA PITUACH, Israel, Nov. 25, ... "Immune" or "the Company"), a clinical stage biopharmaceutical ... of targeted therapeutics for the treatment of inflammatory ... its previously announced underwritten public offering of 3,450,000 ... of the Company,s common stock, par value $0.0001 ...
(Date:11/24/2014)... SAN DIEGO , Nov. 24, 2014  Arena Pharmaceuticals, ... is scheduled to present a corporate overview and update at ... Tuesday, December 2, 2014, at 8:30 a.m. Eastern Time (5:30 ... New York . A live ... investor relations section of Arena,s website at www.arenapharm.com . ...
Breaking Medicine Technology:Unilife to Present at the Piper Jaffray 26th Annual Healthcare Conference on December 2nd 2Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 2Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 3Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 4Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 5Arena Pharmaceuticals to Present at Piper Jaffray 26th Annual Healthcare Conference 2Arena Pharmaceuticals to Present at Piper Jaffray 26th Annual Healthcare Conference 3
... N.J., March 8, 2012  Janssen Research & Development, ... Phase 3 study of ZYTIGA® (abiraterone acetate) plus ... symptomatic patients with metastatic castration-resistant prostate cancer (CRPC) ... Study COU-AA-302 is an international, randomized, double-blind, placebo ...
... AMSTERDAM, March 8, 2012  Leading events organiser UBM Live ... announced an addition to the CPhI Japan events line-up ... Sight Exhibition Centre from 21-23 March, 2012. The Pharmatech ... technology for the Pharma, biopharma, veterinary and medical industries, ...
Cached Medicine Technology:Study Unblinded: ZYTIGA® (abiraterone acetate) Plus Prednisone for Asymptomatic or Mildly Symptomatic Chemotherapy-Naive Patients with Metastatic Castration-Resistant Prostate Cancer 2Study Unblinded: ZYTIGA® (abiraterone acetate) Plus Prednisone for Asymptomatic or Mildly Symptomatic Chemotherapy-Naive Patients with Metastatic Castration-Resistant Prostate Cancer 3Study Unblinded: ZYTIGA® (abiraterone acetate) Plus Prednisone for Asymptomatic or Mildly Symptomatic Chemotherapy-Naive Patients with Metastatic Castration-Resistant Prostate Cancer 4Study Unblinded: ZYTIGA® (abiraterone acetate) Plus Prednisone for Asymptomatic or Mildly Symptomatic Chemotherapy-Naive Patients with Metastatic Castration-Resistant Prostate Cancer 5Study Unblinded: ZYTIGA® (abiraterone acetate) Plus Prednisone for Asymptomatic or Mildly Symptomatic Chemotherapy-Naive Patients with Metastatic Castration-Resistant Prostate Cancer 6New Pharmatech Event to be Introduced Alongside CPhI and P-MEC Japan 2New Pharmatech Event to be Introduced Alongside CPhI and P-MEC Japan 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: